Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

other biologic drugs like GlaxoSmithKline's Nucala (mepolizumab). It is the second indication for the IL-4 and IL-13 inhibitor cleared for use by the NHS in England and Wales after atopic ...

while current biologics – including GSK’s IL-5 inhibitor Nucala (mepolizumab) – are restricted to patients with asthma associated with Type 2 (T2) inflammation. GSK, meanwhile, also bought ...

A new study published in the journal of Respiratory Investigation showed that in actual clinical practice, starting a ...